Tom Reynolds is the President of NEXT Molecular Analytics.  In his previous professional positions, Reynolds was a co-founder of Commonwealth Biotechnologies, Inc, the predecessor company to NEXT Molecular Analytics, founded in 1992, and continuously served as its Executive Vice President, Director, and Secretary. Reynolds helped take CBI public in 1997, with an IPO and listing on NASDAQ. In 2009 Reynolds and Dr. Harris spun out US based operations of CBI into a private company, AIBioTech, LLC. Expertise in clinical molecular diagnostics and genetics, woman's health testing, next generation sequencing and personal medicine related technologies, as well as operation of BSL-3 labs. Subject matter expert in biodefense/bio-crime and human DNA forensics areas. From 1987 until 1997, Reynolds was in the Department of Microbiology Biology and Immunology at Virginia Commonwealth University where he served as Manager of the Nucleic Acids Core Laboratory as part of the Massey Cancer Center. Reynolds is a co-inventor of US patents, and co-author of more than 45 peer reviewed journal articles and book chapters, in the research area of molecular genetics.

Dr. Harris is the current Chief Financial Officer and Chief Scientific Officer of NEXT Molecular Analytics.  In his previous professional positions, Harris was a co-founder of Commonwealth Biotechnologies, Inc, the predecessor company to NEXT Molecular Analytics, founded in 1992, and continuously served as its President, Director, and CEO. Then, Harris served as President and CSO of American International Biotechnology LLC. Until 1997, Dr. Harris was employed in the Department of Biochemistry and Molecular Biophysics at Virginia Commonwealth University, rising through the academic ranks to full Professor. Dr. Harris received a joint Bachelor’s degree in Chemistry and Biology from the University of Rochester, Rochester, NY, and the Master’s and Doctoral degrees from New York University, in Biochemistry and Biophysical Chemistry. Dr. Harris is the co-author of more than 75 peer reviewed journal articles and book chapters, mostly in areas of his research expertise: the role of macromolecular structure in biological function. Dr. Harris is a former Established Investigator of the American Heart Association, and is co-inventor of US and foreign patents.

Mr. Meyers is currently the Chief Operating Officer (COO) of NEXTMolecular Analytics. Previously, he was Vice President of DNA Services at American International Biotechnology, LLC., in Richmond, VA.  He was responsible for oversight and direction of, among other labs, the clinical molecular diagnostic lab where he designed and led the development and validation of several next generation sequencing diagnostic assays used for clinical practice.  Prior to that, he served as a Senior Systems Analyst for Analytic Services, Inc. (ANSER), providing advisory and assistance service support to the Department of Defense Transformational Medical Technologies program, serving as a subject matter expert focused mainly on the areas of pathogen identification and characterization and bioinformatics.  Prior to joining ANSER, Mr. Meyers was a Group Leader, DNA Services, Commonwealth Biotechnologies, Inc., where he oversaw laboratory operations and scientific program direction of molecular biology, DNA sequencing, and microbial forensic and diagnostic service areas, and Project Manager, Icoria, Inc. where he was responsible for all project management aspects of $55million agricultural genomics collaboration between Monsanto Inc. and Icoria.  Mr. Meyers received his BS degree from Virginia Tech in Biology, with an emphasis on microbiology, and his MS degree from VCU/MCV in Microbiology and Immunology.  Mr. Meyers is the author of numerous peer reviewed publications and is a co-inventor on several US patents.